- |||||||||| lithium carbonate ER / Generic mfg.
Trial termination, HEOR: Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) - Feb 15, 2024
P=N/A, N=1037352, Terminated,
Trial completion date: Mar 2026 --> Jul 2026 Completed --> Terminated; Per PI, this study is not a clinical trial and was inadvertently entered in the system
- |||||||||| Chantix (varenicline) / Pfizer, bupropion sustained-release / Generic mfg.
Clinical, Journal: A randomized, double-blind, placebo-controlled, multicentre trial on the efficacy of varenicline and bupropion in combination and alone for treatment of alcohol use disorder: Protocol for the COMB study. (Pubmed Central) - Jan 15, 2024
P2
The COMB Study aims to evaluate the efficacy of the combination of varenicline and bupropion, two drugs affecting dopamine, on alcohol consumption, and to challenge the low-dopamine hypothesis of addiction. Study Code COMB-BO8, EudraCT 2018-000048-24, Version 3.2, Lid
- |||||||||| bupropion sustained-release / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya (clinicaltrials.gov) - Aug 15, 2023
P3, N=300, Completed,
. Recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2023 | Trial primary completion date: Dec 2024 --> Jul 2023
- |||||||||| Chantix (varenicline) / Pfizer
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Embedding Comprehensive Smoking Cessation Programs Into Community Clinics (clinicaltrials.gov) - Aug 14, 2023
P=N/A, N=406, Completed,
Recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2023 | Trial primary completion date: Dec 2024 --> Jul 2023 Recruiting --> Completed | N=1200 --> 406 | Trial completion date: Jun 2023 --> Nov 2022 | Trial primary completion date: Jun 2023 --> Nov 2022
- |||||||||| Chantix (varenicline) / Pfizer
Ascertaining Evidence and Strategies for Medical Treatment of Adolescents With Substance Use Disorders (SUD) (Room 153, Moscone South Room Level: Upper Mezzanine) - Jan 29, 2023 - Abstract #APA2023APA_286;
This session is intended to examine, identify, and evaluate the various means of psychotropic medical management of SUD in the adolescent population to improve the clinical care and medical management of this highly vulnerable population. While management is multidisciplinary and complex, both FDA-approved and off-label uses of MAT show great promise for this demographic and act in the continued battle against the opioid epidemic, aiding in apt management, reduced stigma, improved quality of life, and increased societal integration of these adolescents and young adults.Learning Objectives Objective One: To identify diagnostic criteria and recognize presentations of substance use disorders (SUD) in adolescents, including opioid use disorder (OUD), alcohol use disorder (AUD), and cannabis use disorder Objective Two: To categorize and assess varying evidence, efficacy, risks, and indications of MAT in adolescents, including NAC, naltrexone, disulfiram, acamprosate, NRT, buproprion-S Objective Three: To elucidate and establish evidence-based practices for medication-assisted management of adolescents with substance use disorders (SUD) Objective Four: Objective Five:
- |||||||||| Auvelity (bupropion/dextromethorphan) / Axsome Therap
Journal: Dextromethorphan/bupropion (Auvelity) for depression. (Pubmed Central) - Dec 22, 2022
While management is multidisciplinary and complex, both FDA-approved and off-label uses of MAT show great promise for this demographic and act in the continued battle against the opioid epidemic, aiding in apt management, reduced stigma, improved quality of life, and increased societal integration of these adolescents and young adults.Learning Objectives Objective One: To identify diagnostic criteria and recognize presentations of substance use disorders (SUD) in adolescents, including opioid use disorder (OUD), alcohol use disorder (AUD), and cannabis use disorder Objective Two: To categorize and assess varying evidence, efficacy, risks, and indications of MAT in adolescents, including NAC, naltrexone, disulfiram, acamprosate, NRT, buproprion-S Objective Three: To elucidate and establish evidence-based practices for medication-assisted management of adolescents with substance use disorders (SUD) Objective Four: Objective Five: No abstract available
- |||||||||| bupropion sustained-release / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: Integrating Tobacco Use Cessation Into HIV Care and Treatment in Kisumu County, Kenya (clinicaltrials.gov) - Oct 6, 2022
P4, N=580, Not yet recruiting,
Our findings suggest that, during a period when e-cigarettes are widely available, cigarette tax increases remain effective in increasing use of these medications, but e-cigarette taxes do not increase use of these medications. Trial completion date: Aug 2026 --> Nov 2024 | Initiation date: Sep 2022 --> May 2023 | Trial primary completion date: Sep 2023 --> Nov 2024
- |||||||||| zonisamide / Generic mfg.
Trial completion date, Trial primary completion date: The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette (clinicaltrials.gov) - Aug 23, 2022
P3, N=180, Recruiting,
Trial completion date: Aug 2026 --> Nov 2024 | Initiation date: Sep 2022 --> May 2023 | Trial primary completion date: Sep 2023 --> Nov 2024 Trial completion date: Mar 2023 --> Aug 2023 | Trial primary completion date: Dec 2022 --> May 2023
- |||||||||| bupropion sustained-release / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date: PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness (clinicaltrials.gov) - Aug 11, 2022
P4, N=120, Recruiting,
Trial completion date: Mar 2023 --> Aug 2023 | Trial primary completion date: Dec 2022 --> May 2023 N=60 --> 120 | Trial completion date: Jul 2022 --> Jul 2025 | Trial primary completion date: Jul 2022 --> Jul 2025
- |||||||||| aripiprazole / Generic mfg., bupropion sustained-release / Generic mfg., fluoxetine / Generic mfg.
Serotonin Syndrome in a 50-Year-Old Female: A Case Report () - May 5, 2022 - Abstract #APA2022APA_635;
She was on several psychotropic medications: bupropion SR 200 mg twice daily, fluoxetine 40 mg twice daily, lamotrigine 200 mg twice daily, and buspirone 15 mg twice daily...The patient’s bupropion SR dosage was decreased to 150 mg twice daily and aripiprazole 5 mg daily was started for the hallucinations...While the true incidence of SS is unknown, it is commonly seen in patients prescribed SSRIs. Prevention and recognition of this potentially life-threatening syndrome should be at the forefront of anyone prescribing serotonergic agents, especially psychiatrists.
- |||||||||| zonisamide / Generic mfg.
Trial completion: BuZonE: Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes (clinicaltrials.gov) - Mar 29, 2022
P3, N=26, Completed,
Prevention and recognition of this potentially life-threatening syndrome should be at the forefront of anyone prescribing serotonergic agents, especially psychiatrists. Active, not recruiting --> Completed
- |||||||||| Chantix (varenicline) / Pfizer
Trial completion, Trial completion date: Individualizing Pharmacotherapy for African American Smokers (clinicaltrials.gov) - Mar 10, 2022
P3, N=392, Completed,
For a subset of patients who chose to add BUP-SR to their behavioral therapy, fatigue improves further but not to a statistically significant effect compared to behavioral therapy alone. Active, not recruiting --> Completed | Trial completion date: May 2023 --> Jan 2022
- |||||||||| Chantix (varenicline) / Pfizer
Trial primary completion date: Individualizing Pharmacotherapy for African American Smokers (clinicaltrials.gov) - Mar 9, 2022
P3, N=392, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: May 2023 --> Jan 2022 Trial primary completion date: Apr 2022 --> Jan 2022
- |||||||||| Chantix (varenicline) / Pfizer
Phase classification: Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH) (clinicaltrials.gov) - Feb 16, 2022
P4, N=12, Completed,
Further work on the importance of sex as a biological variable and how the complex interoceptive stimulus effects of nicotine can vary with training histories is needed. Phase classification: P=N/A --> P4
- |||||||||| bupropion sustained-release / Generic mfg.
Zyban (Twitter) - Feb 11, 2022
- |||||||||| bupropion sustained-release / Generic mfg., sertraline / Generic mfg.
Clinical, Review, Journal: Childhood maltreatment history for guiding personalized antidepressant choice in major depressive disorder: Preliminary results from a systematic review. (Pubmed Central) - Jan 15, 2022
Further, sertraline and the group of antidepressants with low affinity for the serotonin transporter may be less suitable for MDD patients with childhood abuse history than escitalopram, venlafaxine-XR, or antidepressants with high affinity for the serotonin transporter. The critical question of the most potentially efficacious treatment regimens for adult MDD with CM history requires further large-sample studies involving a greater number of medications, specifically designed to analyse the moderating effects of different types of CM, and possibly including objective biomarkers.
- |||||||||| Chantix (varenicline) / Pfizer
Trial completion, Trial completion date: Combining Varenicline and Bupropion for Smoking Cessation (clinicaltrials.gov) - Dec 7, 2021
P3, N=641, Completed,
The critical question of the most potentially efficacious treatment regimens for adult MDD with CM history requires further large-sample studies involving a greater number of medications, specifically designed to analyse the moderating effects of different types of CM, and possibly including objective biomarkers. Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021
- |||||||||| bupropion sustained-release / Generic mfg., bupropion / Generic mfg.
Clinical, Journal: Placebo-Controlled Trial of Bupropion for Smoking Cessation in Pregnant Women. (Pubmed Central) - Nov 29, 2021
P2
Although bupropion use was not associated with elevated risk of pregnancy complications when initiated in the second trimester, it did not increase the likelihood of smoking cessation in this sample of pregnant women. Because smoking is the major preventable source of poor pregnancy outcomes and psychosocial interventions have only modest beneficial effects, additional studies are needed to identify safe and efficacious smoking cessation medications for pregnant women who continue to smoke.
- |||||||||| bupropion sustained-release / Generic mfg.
Journal: 5-HT and 5-HT receptors as potential targets for the treatment of nicotine use and dependence. (Pubmed Central) - Nov 29, 2021
There are currently three main forms of pharmacotherapy approved as aids to treat nicotine dependence: a variety of nicotine replacement products (NRT's), the mixed NA/DA reuptake inhibitor bupropion (Zyban®), and the preferential nicotinic α4β2 receptor agonist drug, varenicline (Chantix®); the latter being generally recognized to be the most effective...Additional avenues include 5-HT2C receptor agonists, which until recently was pioneered by lorcaserin, and 5-HT2A receptor antagonists represented by pimavanserin...It is anticipated as diagnostic and predictive biomarkers emerge, they may provide opportunities for subject stratification and opportunities for personalizing smoking cessation treatment. The clinical assessment of SSRI, 5-HT2A and/or 5-HT2C receptor-based treatments may be best served by this process.
- |||||||||| bupropion sustained-release / Generic mfg.
Trial completion date, Trial primary completion date: Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya (clinicaltrials.gov) - Nov 3, 2021
P3, N=300, Recruiting,
The clinical assessment of SSRI, 5-HT2A and/or 5-HT2C receptor-based treatments may be best served by this process. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| lithium carbonate ER / Generic mfg.
Trial completion, HEOR: Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) - Oct 7, 2021
P=N/A, N=1037352, Completed,
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Enrolling by invitation --> Completed
- |||||||||| Chantix (varenicline) / Pfizer
Trial completion date, Trial primary completion date: Embedding Comprehensive Smoking Cessation Programs Into Community Clinics (clinicaltrials.gov) - Aug 25, 2021
P=N/A, N=1200, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Jun 2023
- |||||||||| bupropion sustained-release / Generic mfg.
Trial completion date, Trial primary completion date: PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness (clinicaltrials.gov) - Aug 18, 2021
P4, N=60, Recruiting,
Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Jun 2023 Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
|
